However, while SGLT-2 inhibitors can reduce the risk of kidney failure and cardiovascular events and provide improvements in glycemic control, neither this drug class nor (ns)MRAs markedly address obesity per se. This evidence concerns the gene SLC5A2 and obesity disorder.